Baijin Life Science (HKG:1466) said it expects to post a net profit of about HK$2.5 million for the six months ended Sept. 30, compared with a loss of roughly HK$1.9 million a year earlier, according to a Tuesday Hong Kong bourse filing.
The improvement for the fiscal first half is mainly driven by a gain from the change in fair value of a convertible bond, partly offset by lower gross profit, the company said.
Full interim results are scheduled for release on Nov. 27.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.